Overexpressed MET drives aggressive thyroid cancer phenotypes and serves as a precision therapeutic target.

ABSTRACT: The global incidence of thyroid carcinoma (THCA) is increasing. Although generally indolent with a favorable prognosis, a subset of cases exhibits aggressive progression. Conventional chemotherapy frequently induces severe systemic toxicity owing to poor target specificity, highlighting the need for more targeted therapeutic approaches. The HGF/c-MET signaling pathway plays a pivotal role in tumorigenesis and disease progression, promoting malignant tumor development through diverse mechanisms, including cell proliferation and migration. By combining integrated multi-omics bioinformatics analysis with functional experiments, this study demonstrates that the MET gene represents a promising theragnostic marker for THCA. Specifically, our study demonstrated: (1) The MET gene is significantly

SUBMITTER: Xu R 

PROVIDER: S-EPMC12615610 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature